Track topics on Twitter Track topics that are important to you
WINNIPEG, Manitoba, March 14, 2017 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS"), is pleased to announce that it recently made the final payment to CancerCare Manitoba (“CCMB”) for the purchase of intellectual property. All patents were assigned from CCMB to 3DS on June 26, 2014. Quarterly cash payments made by 3DS to CCMB totaled $269,617.75 over a 24 month period. CCMB retains a 1.5% royalty on all gross revenues derived from the commercialization of the patent rights and related products.
“CCBM has been an excellent partner and we see a number of opportunities for further collaboration based on some very recent and productive discussions,” noted Jason Flowerday, CEO of 3DS. “The intellectual property acquired from CCMB is at the core of our proprietary TeloViewTM software platform, which, to-date, has successfully identified and correlated distinct 3D telomere signatures in 13 different cancers and Alzheimer’s disease. We believe that TeloViewTM is a valuable and disruptive technology that will lead to multiple commercial tests as well as collaborations with biopharma partners that share our commitment to personalized medicine.”
3DS (TSXV:DXD) (OTCQB:TDSGF) (FSE:3D0) is a personalized medicine company with a proprietary software platform based on the three-dimensional analysis of chromosomal signatures. The technology is well developed and supported by 22 clinical studies on over 2,000 patients on 13 different cancers and Alzheimer’s disease. Depending on the desired application, this platform technology can measure the stage of disease, rate of progression of disease, drug efficacy, and drug toxicity. The technology is designed to predict the course of disease and to personalize treatment for the individual patient. For more information, visit the Company’s new website at http://www.3dsignatures.com.
This news release includes forward-looking statements that are subject to risks and uncertainties. Forward-looking statements involve known and unknown risks, uncertainties, and other factors that could cause the actual results of the Company to be materially different from the historical results or from any future results expressed or implied by such forward-looking statements. All statements within, other than statements of historical fact, are to be considered forward looking. Although 3DS believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Risk factors that could cause actual results or outcomes to differ materially from the results expressed or implied by forward-looking information include, among other things: market demand; technological changes that could impact the Company’s existing products or the Company’s ability to develop and commercialize future products; competition; existing governmental legislation and regulations and changes in, or the failure to comply with, governmental legislation and regulations; the ability to manage operating expenses, which may adversely affect the Company’s financial condition; the Company’s ability to successfully maintain and enforce its intellectual property rights and defend third-party claims of infringement of their intellectual property rights; adverse results or unexpected delays in clinical trials; changes in laws, general economic and business conditions; and changes in the regulatory regime. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements.
Neither the TSX Venture Exchange nor its Regulation Service Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information, please contact: Stephen Kilmer Investor Relations 647-872-4849 firstname.lastname@example.org OR Hugh Rogers VP Corporate Finance 604-250-6162 email@example.comNEXT ARTICLE
Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...